Genentech Enters Type 1 Diabetes Space In Licensing Deal With Bayhill
This article was originally published in The Pink Sheet Daily
Transaction offers an example of how Genentech and Roche’s business development arms will operate post-merger.
You may also be interested in...
Of the two recent events with major implications for Biogen Idec’s multiple sclerosis franchise, the less prominent – the acquisition of Fumapharm, its partner on the experimental oral MS therapeutic BG-12 – could, in the long run, be more significant than the re-approval of Tysabri.
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.